Haemonetics Co. (NYSE:HAE) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. trimmed its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 99.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,237 shares of the medical instruments supplier's stock after selling 3,281,763 shares during the period. D. E. Shaw & Co. Inc.'s holdings in Haemonetics were worth $1,424,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Boston Trust Walden Corp lifted its stake in Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after purchasing an additional 106,114 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of Haemonetics during the 4th quarter valued at about $319,000. Pacer Advisors Inc. raised its holdings in shares of Haemonetics by 36.1% during the 4th quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock valued at $789,000 after buying an additional 2,680 shares in the last quarter. Norges Bank bought a new stake in Haemonetics in the 4th quarter worth approximately $32,803,000. Finally, Voya Investment Management LLC grew its position in Haemonetics by 820.5% during the fourth quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after acquiring an additional 282,521 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Performance

HAE traded down $0.88 during midday trading on Wednesday, hitting $67.11. 26,877 shares of the company were exchanged, compared to its average volume of 680,406. Haemonetics Co. has a 1-year low of $55.30 and a 1-year high of $94.99. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of 26.44, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The company's 50 day simple moving average is $63.22 and its 200 day simple moving average is $70.72.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.02. The firm had revenue of $330.60 million during the quarter, compared to analysts' expectations of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The business's revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.90 EPS. As a group, sell-side analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HAE. Wall Street Zen cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Barrington Research reduced their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Raymond James reissued a "strong-buy" rating and issued a $105.00 target price (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Needham & Company LLC cut their price objective on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $100.00 target price on shares of Haemonetics in a research note on Tuesday, May 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $97.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.